Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

While there have been massive strides forward in treating cancer in the last decades – with a doubling in survival rates in the last ... and an ongoing lung cancer screening drive rolled out ...

In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI ® ). Currently, there are twelve approved indications for ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC ... with this form of cancer typically have a five-year survival rate of just 7%, with few treatment ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

In patients with advanced squamous non–small cell lung cancer, ivonescimab plus chemo was associated with progression-free ...

Summit Therapeutics shares rallied after its lung cancer drug candidate showed that it improved patients' longevity without the disease worsening in a late-stage trial. Shares of Summit rose 11% to ...